AstraZeneca Results Presentation Deck
BioPharmaceuticals:
New CVRM
Farxiga inflection point; strong progress
$m
1,000
800
600
400
200-
Q1 2018
Q2 2018
Q3 2018
Diabetes/HF: 9% growth driven by Farxiga, continued
the fastest-growing SGLT2¹ in the fastest-growing T2D² class³
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Farxiga Onglyza Bydureon Byetta Other
Total revenue at actual exchange rates; changes at CER and for FY 2020, unless stated
otherwise.
15
●
Farxiga +30%
US +6%
Strong market growth
offset by some price
Ex US (71% of total)
Europe +35%
Strong volume growth; SGLT2
leadership in several markets
EMs +55%
Leading SGLT2; benefit from NRDL
1. Sodium-glucose co-transporter 2 (inhibitor).
2. Type-2 diabetes.
3. IQVIA market research.
$m
500
400
300
200
Brilinta +2%: COVID-19 impact in all
regions and China
VBP4
price change
100-
Q1 2018
Brilinta: growth
impacted by COVID-19
Q2 2018
Q4
Q3 2018
2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
US Europe EROW EMs
Total revenue at actual exchange rates; changes at CER and for FY 2020,
unless stated otherwise. 4. Volume-based procurement.
Q3 2020
Q4 2020
4View entire presentation